ATOS | 63.22 / -0.03% |
Date/Time | 03/05 / 17:35 |
Chg. / Chg.(%) | -0.02 / -0.03% |
Bid | 63.20 / 50 |
Ask | 63.66 / 42 |
Open | 62.80 |
Previous Close | 63.24 |
High | 63.62 |
Low | 62.30 |
Volume [EUR] | 35,248,839.48 |
Volume [Units] | 628,443 |
Price fixings | 8442 |
ISIN | FR0000051732 |
Security | ATO |
Exchange | Euronext - Paris |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 64.060 | ![]() |
|
Euronext - P.. | 63.22 | ![]() |
628,443 |
Cboe Europe .. | 63.22 | ![]() |
114,113 |
London Inter.. | 63.43 | ![]() |
43,241 |
Turquoise | 63.34 | ![]() |
39,267 |
TradeGate | 63.580 | ![]() |
1,589 |
Frankfurt | 63.1600 | ![]() |
300 |
Cboe Europe .. | 63.57 | ![]() |
280 |
Vienna Globa.. | 63.32 | ![]() |
267 |
gettex | 63.980 | ![]() |
242 |
Cboe Europe .. | 63.50 | ![]() |
23 |
Berlin | 62.74 | ![]() |
0 |
Düsseldorf | 63.74 | ![]() |
0 |
München | 63.04 | ![]() |
0 |
Stuttgart | 63.140 | ![]() |
0 |
Nasdaq Other.. | 76.7392 | 112 | |
EUREX | Options |
News
- Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
02/25/2021 / 15:00 - GlobeNewswire - Europe closes in red, FTSE sinks over 1%
02/18/2021 / 17:31 - TeleTrader - Lexington Realty Trust Reports Fourth Quarter 2020 Results
02/18/2021 / 12:00 - GlobeNewswire - Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021
02/10/2021 / 15:30 - GlobeNewswire - Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen
02/03/2021 / 15:30 - GlobeNewswire